<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000752</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 186</org_study_id>
    <nct_id>NCT00000752</nct_id>
  </id_info>
  <brief_title>Preventing Frequent Sinus Infections in HIV-Infected Patients</brief_title>
  <official_title>Management of HIV-Infected Patients at Risk of Recurrent Purulent Sinusitis: Role of Anti-Inflammatory, Antibacterial, and Decongestant Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adams Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate the additional effectiveness of an anti-inflammatory nasal spray ( beclomethasone&#xD;
      dipropionate ) and a broad spectrum antibiotic ( cefuroxime axetil ) over decongestant (&#xD;
      Deconsal II ) alone, when these agents are given individually or in combination for the&#xD;
      prevention of recurrent paranasal sinus infection in patients with HIV infection. To compare&#xD;
      the clinical utility of paranasal sinus radiographs with computed tomograms (CTs) in the&#xD;
      evaluation and management of HIV-infected patients with recurrent paranasal sinus infection.&#xD;
      To determine relevant prognostic factors and the microbiologic etiology of maxillary&#xD;
      sinusitis in this patient population.&#xD;
&#xD;
      Sinusitis is common among HIV-infected patients and is likely to be recurrent or refractory&#xD;
      to traditional therapy, particularly in patients with advanced immunosuppression. An&#xD;
      intervention aimed at prevention of recurrent sinus disease in HIV-infected patients appears&#xD;
      to be warranted.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sinusitis is common among HIV-infected patients and is likely to be recurrent or refractory&#xD;
      to traditional therapy, particularly in patients with advanced immunosuppression. An&#xD;
      intervention aimed at prevention of recurrent sinus disease in HIV-infected patients appears&#xD;
      to be warranted.&#xD;
&#xD;
      Patients receive 21-42 days of antibiotic therapy for the defining episode of sinusitis.&#xD;
      Following discontinuation of antibiotics, screening evaluations are performed. Within 7 days&#xD;
      following completion of antibiotics, patients with clinical resolution begin 14 +/- 3 days of&#xD;
      decongestant therapy with oral Deconsal II, a drug combining pseudoephedrine, a decongestant,&#xD;
      and guaifenesin, an expectorant. Following decongestant therapy, patients undergo entry&#xD;
      evaluations, including nasal endoscopy and sinus radiograph. Patients with continued clinical&#xD;
      resolution and no purulence on endoscopy are then randomized to receive decongestant alone or&#xD;
      in combination with nasal steroid (beclomethasone dipropionate) or antibiotic (cefuroxime&#xD;
      axetil) or both. Treatment continues for a minimum of 52 weeks and a maximum of 104 weeks.&#xD;
      Patients are followed at weeks 4, 8, and 12 and every 8 weeks thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <completion_date type="Actual">February 1993</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV Infections</condition>
  <condition>Sinusitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pseudoephedrine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guaifenesin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefuroxime axetil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beclomethasone dipropionate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antiretroviral agents (both approved and investigational).&#xD;
&#xD;
          -  Biologic response modifiers.&#xD;
&#xD;
          -  Systemic chemotherapy.&#xD;
&#xD;
          -  Chemoprophylaxis for Pneumocystis carinii pneumonia (PCP), candidiasis, and herpes.&#xD;
&#xD;
          -  Adjuvant systemic corticosteroids with appropriate antibiotic therapy for moderate to&#xD;
             severe PCP.&#xD;
&#xD;
          -  Maintenance therapy with pyrimethamine, sulfadiazine, amphotericin B, fluconazole,&#xD;
             ketoconazole, or acyclovir.&#xD;
&#xD;
          -  Treatment with ganciclovir, foscarnet, or antimycobacterial drugs for CMV disease or&#xD;
             mycobacterial infections.&#xD;
&#xD;
          -  Non-beta lactam antibacterial agents for other infections (beta lactam antibacterial&#xD;
             agents are allowed if study drugs are temporarily discontinued).&#xD;
&#xD;
          -  Antihistamines and saline nasal sprays.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Radiation therapy.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  At least one episode of symptomatic maxillary sinusitis, with clinical resolution&#xD;
             following antibiotic therapy.&#xD;
&#xD;
          -  Life expectancy of at least 12 months.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Concurrent infection caused by cytomegalovirus or Mycobacterium avium Complex.&#xD;
&#xD;
          -  Significant emotional disorder or psychosis.&#xD;
&#xD;
          -  Conditions such as dementia that would substantially impair study compliance.&#xD;
&#xD;
          -  Evidence of significant malabsorption, ileus, or significant emesis that would inhibit&#xD;
             drug absorption.&#xD;
&#xD;
          -  Inability to tolerate a minimum administration of one tablet of oral Deconsal II&#xD;
             daily.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prescription or over-the-counter nasal steroids, decongestants, or topical&#xD;
             vasoconstrictors (ephedrine, oxymetazoline).&#xD;
&#xD;
        Patients with the following prior condition are excluded:&#xD;
&#xD;
          -  History of an acute hypersensitivity reaction to any penicillin or cephalosporin,&#xD;
             characterized by urticaria, hypotension, or laryngeal edema.&#xD;
&#xD;
        Active substance abuse that would impair study compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J Zurlo</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>JA McCutchan</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Univ of California / San Diego Treatment Ctr</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>921036325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford at Kaiser / Kaiser Permanente Med Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Drug Treatment Ctr / Bronx Municipal Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Family Health Ctr / Bronx Municipal Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samaritan Village Inc / Bronx Municipal Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jack Weiler Hosp / Bronx Municipal Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10465</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Med Ctr / Bronx Municipal Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Med Ctr Adolescent AIDS Program</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Central Bronx Hosp / Bronx Municipal Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson Univ Hosp</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>191075098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zurlo JJ, Feuerstein IM, Lebovics R, Lane HC. Sinusitis in HIV-1 infection. Am J Med. 1992 Aug;93(2):157-62. doi: 10.1016/0002-9343(92)90045-d.</citation>
    <PMID>1353944</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>cefuroxime axetil</keyword>
  <keyword>Beclomethasone</keyword>
  <keyword>Guaiacol Glyceryl Ether</keyword>
  <keyword>Sinusitis</keyword>
  <keyword>Ephedrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefuroxime</mesh_term>
    <mesh_term>Cefuroxime axetil</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Phenylpropanolamine</mesh_term>
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Guaifenesin</mesh_term>
    <mesh_term>Chlorpheniramine, phenylpropanolamine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

